New cytoskeletal proteins are induced in HeLa cells by Vinca alkaloids. 1988

Y Maehara, and H Kusumoto, and H Anai, and T Kusumoto, and K Sugimachi
Cancer Center of Kyushu University Hospital, Faculty of Medicine, Kyushu University, Fukuoka, Japan.

The effects of Vinca alkaloids, vinblastine, vincristine, and vindesine, on protein synthesis were determined using HeLa cells. Vinblastine at the concentration of 1 microgram/ml induced new proteins, isoelectric points 4.8 and 7.0-7.5 and molecular weights 48 and 92 kd, in the HeLa cells, identified using two-dimensional gel electrophoresis. The 48-kd and the clustered (4-components) 92-kd proteins were also noted in HeLa cells treated with vincristine or vindesine. As most of the 48- and 92-kd proteins were Triton insoluble, they can be considered components of the cytoskeletal structure. Syntheses of these proteins were blocked by actinomycin D, therefore, new messenger RNA synthesis is required for induction. These proteins were not induced by an alkylating agent, antitumor antibiotics, or an antimetabolite. Our findings show that the 48- and the clustered 92-kd proteins are Vinca alkaloid reactive components and can be considered candidates for the elucidation of the antineoplastic effect of Vinca alkaloids.

UI MeSH Term Description Entries
D008937 Mitomycins A group of methylazirinopyrroloindolediones obtained from certain Streptomyces strains. They are very toxic antibiotics used as ANTINEOPLASTIC AGENTS in some solid tumors. PORFIROMYCIN and MITOMYCIN are the most useful members of the group.
D002225 Carbazilquinone An alkylating agent structurally similar to MITOMYCIN and found to be effective in the treatment of leukemia and various other neoplasms in mice. It causes leukemia and thrombocytopenia in almost all human patients. Carboquinone,Carboquone,Esquinon
D003598 Cytoskeletal Proteins Major constituent of the cytoskeleton found in the cytoplasm of eukaryotic cells. They form a flexible framework for the cell, provide attachment points for organelles and formed bodies, and make communication between parts of the cell possible. Proteins, Cytoskeletal
D005786 Gene Expression Regulation Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation. Gene Action Regulation,Regulation of Gene Expression,Expression Regulation, Gene,Regulation, Gene Action,Regulation, Gene Expression
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013268 Stimulation, Chemical The increase in a measurable parameter of a PHYSIOLOGICAL PROCESS, including cellular, microbial, and plant; immunological, cardiovascular, respiratory, reproductive, urinary, digestive, neural, musculoskeletal, ocular, and skin physiological processes; or METABOLIC PROCESS, including enzymatic and other pharmacological processes, by a drug or other chemical. Chemical Stimulation,Chemical Stimulations,Stimulations, Chemical
D014748 Vinca Alkaloids A group of indole-indoline dimers which are ALKALOIDS obtained from the VINCA genus of plants. They inhibit polymerization of TUBULIN into MICROTUBULES thus blocking spindle formation and arresting cells in METAPHASE. They are some of the most useful ANTINEOPLASTIC AGENTS. Alkaloids, Vinca
D016685 Mitomycin An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis. Mitomycin C,Ametycine,Mitocin-C,Mitomycin-C,Mutamycin,NSC-26980,Mitocin C,MitocinC,NSC 26980,NSC26980

Related Publications

Y Maehara, and H Kusumoto, and H Anai, and T Kusumoto, and K Sugimachi
June 1968, Nature,
Y Maehara, and H Kusumoto, and H Anai, and T Kusumoto, and K Sugimachi
January 1979, The New England journal of medicine,
Y Maehara, and H Kusumoto, and H Anai, and T Kusumoto, and K Sugimachi
April 1989, Planta medica,
Y Maehara, and H Kusumoto, and H Anai, and T Kusumoto, and K Sugimachi
December 1992, Seminars in oncology,
Y Maehara, and H Kusumoto, and H Anai, and T Kusumoto, and K Sugimachi
May 1981, Lancet (London, England),
Y Maehara, and H Kusumoto, and H Anai, and T Kusumoto, and K Sugimachi
January 1968, Transactions of the American Neurological Association,
Y Maehara, and H Kusumoto, and H Anai, and T Kusumoto, and K Sugimachi
October 1965, Revue neurologique,
Y Maehara, and H Kusumoto, and H Anai, and T Kusumoto, and K Sugimachi
December 1989, Current opinion in oncology,
Y Maehara, and H Kusumoto, and H Anai, and T Kusumoto, and K Sugimachi
January 1987, Cancer chemotherapy and biological response modifiers,
Y Maehara, and H Kusumoto, and H Anai, and T Kusumoto, and K Sugimachi
January 1988, Cancer chemotherapy and biological response modifiers,
Copied contents to your clipboard!